REYON Pharmaceutical Statistics

Total Valuation

REYON Pharmaceutical has a market cap or net worth of KRW 253.11 billion. The enterprise value is 468.38 billion.

Market Cap	253.11B
Enterprise Value	468.38B

Important Dates

The next estimated earnings date is Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

REYON Pharmaceutical has 18.34 million shares outstanding. The number of shares has decreased by -0.90% in one year.

Shares Outstanding	18.34M
Shares Change (YoY)	-0.90%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	61.21%
Owned by Institutions (%)	0.63%
Float	6.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.72
PB Ratio	1.03
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 102.51, with an EV/FCF ratio of -21.08.

EV / Earnings	-4,483.73
EV / Sales	3.14
EV / EBITDA	102.51
EV / EBIT	n/a
EV / FCF	-21.08

Financial Position

The company has a current ratio of 0.65, with a Debt / Equity ratio of 0.90.

Current Ratio	0.65
Quick Ratio	0.36
Debt / Equity	0.90
Debt / EBITDA	36.02
Debt / FCF	-10.05
Interest Coverage	9.02

Financial Efficiency

Return on equity (ROE) is -0.04% and return on invested capital (ROIC) is 0.24%.

Return on Equity (ROE)	-0.04%
Return on Assets (ROA)	0.23%
Return on Capital (ROIC)	0.24%
Revenue Per Employee	319.04M
Profits Per Employee	-223,690
Employee Count	467
Asset Turnover	0.30
Inventory Turnover	2.23

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.98% in the last 52 weeks. The beta is 1.00, so REYON Pharmaceutical's price volatility has been similar to the market average.

Beta (5Y)	1.00
52-Week Price Change	-10.98%
50-Day Moving Average	13,794.20
200-Day Moving Average	14,507.35
Relative Strength Index (RSI)	44.93
Average Volume (20 Days)	24,265

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, REYON Pharmaceutical had revenue of KRW 148.99 billion and -104.46 million in losses. Loss per share was -6.00.

Revenue	148.99B
Gross Profit	72.73B
Operating Income	1.84B
Pretax Income	-164.49M
Net Income	-104.46M
EBITDA	6.20B
EBIT	1.84B
Loss Per Share	-6.00

Full Income Statement

Balance Sheet

The company has 7.90 billion in cash and 223.18 billion in debt, giving a net cash position of -215.28 billion or -11,737.56 per share.

Cash & Cash Equivalents	7.90B
Total Debt	223.18B
Net Cash	-215.28B
Net Cash Per Share	-11,737.56
Equity (Book Value)	246.79B
Book Value Per Share	13,455.74
Working Capital	-43.58B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.66 billion and capital expenditures -24.87 billion, giving a free cash flow of -22.21 billion.

Operating Cash Flow	2.66B
Capital Expenditures	-24.87B
Free Cash Flow	-22.21B
FCF Per Share	-1,211.19

Full Cash Flow Statement

Margins

Gross margin is 48.82%, with operating and profit margins of 1.24% and -0.07%.

Gross Margin	48.82%
Operating Margin	1.24%
Pretax Margin	-0.11%
Profit Margin	-0.07%
EBITDA Margin	4.16%
EBIT Margin	1.24%
FCF Margin	-14.91%

Dividends & Yields

This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.08%.

Dividend Per Share	150.00
Dividend Yield	1.08%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.90%
Shareholder Yield	1.99%
Earnings Yield	-0.04%
FCF Yield	-8.78%

Dividend Details

Stock Splits

The last stock split was on December 29, 2020. It was a forward split with a ratio of 1.02.

Last Split Date	Dec 29, 2020
Split Type	Forward
Split Ratio	1.02

Scores

REYON Pharmaceutical has an Altman Z-Score of 1.48. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.48
Piotroski F-Score	n/a